Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie 3Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Abbvie 3Q Results

Revenues up 9% in the quarter despite 55% decline in Humira sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Abbvie

Abbvie

3Q Revenues: $15.8 billion (+9%) 

3Q Earnings: $186 million (earnings were $1.6B 3Q24)

YTD Revenues: $44.5 billion (+8%)

YTD Earnings: $2.4 billion (-44%)

Comments: Global sales from the immunology portfolio were $7.9 billion, up 12%. Skyrizi sales were $4.7 billion, up 47%. Rinvoq sales were $2.2 billion, up 35%. Humira sales were $993 million, down 55%.

Global revenues from the oncology portfolio were flat at $1.7 billion. Imbruvica sales were $706 million, down 15%. Venclexta sales were $726 million, up 7%. Elahere sales were $170 million, up 23%.

Global revenues from the aesthetics portfolio were $1.2 billion, down 4%. Botox Cosmetic sales were $637 million, down 5%. Juvederm sales were $253 million, down 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics